🔗 Share this article

The initial novel therapies for gonorrhoea in many years are being hailed as a "huge turning point" in the battle against increasingly resistant strains of the bacteria, according to scientists.

A Global Health Concern

The sexually transmitted infection are on the rise globally, with estimates suggesting over 82 million infections each year. Especially elevated rates are reported in the African continent and countries within the WHO's Western Pacific region, which spans from Mongolia and China to New Zealand. Across England, cases have reached a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the context of increasing worldwide cases, the spread of superbugs and the highly restricted treatment choices currently available.”

Medical experts are increasingly worried about the surge in antibiotic-resistant strains. The global health body has classified it as a "priority pathogen". Recent surveillance revealed that resistance to primary antibiotics like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Therapies Receive Clearance

Zoliflodacin, also known as a brand name, was approved by the US FDA in December for use against gonorrhoea. This STI can lead to serious health problems, including infertility. Scientists hope that specific application of this new drug will help hinder the development of resistance.

Gepotidacin, originating from the drugmaker GSK, gained clearance in concurrent days. This treatment, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin emerged from a new, not-for-profit approach for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This authorization signifies a significant shift in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”

Testing Data and Global Access

According to data detailed in a major medical journal, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which uses a dual-drug approach. The research involved hundreds of participants from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, GARDP has the authority to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have voiced positive views. Having a one-pill regimen such as this is described as a "revolutionary step" for managing the epidemic. This is considered crucial to alleviate the strain of the disease for people and to prevent the spread of extremely resistant gonorrhoea worldwide.